Drug | Origin | Improvement/function | Phenomenon and characteristics | Year | Reference |
---|---|---|---|---|---|
Ironomycin | Salinomycin | Accumulating and sequestering iron in lysosomes | Iron overload and reactive oxygen species overgeneration | 2017 | [51] |
CSO-SS-Cy7-Hex/SPION/Srfn | Sorafenib, iron | Combined iron and sorafenib | Iron overload, intracellular depletion of glutathione and reactive oxygen species overgeneration | 2019 | [106] |
Erastin@FA-exo | Erastin | TNBC targetting, increased biocompatibility | Intracellular depletion of glutathione and reactive oxygen species overgeneration | 2019 | [107] |
MnO2@HMCu2-xS nanocomposites | Mn2+, rapamycin | Combined Fenton-like reaction by Mn2+ and autophagy by rapamycin | Iron overload and reactive oxygen species overgeneration | 2019 | [108] |
Drug-organics-inorganics self-assembled nanosystem | Doxorubicin, iron, tannic acid | Combined chemotherapy, ferroptosis and superoxide dismutase (SOD)-like reaction | Iron overload and reactive oxygen species overgeneration | 2019 | [109] |
Nanoparticle ferritin-bound erastin and rapamycin | Erastin, rapamycin | Combined ferroptosis and autophagy | GPX4 downregulation and lipid peroxidation accumulation | 2019 | [110] |
Ascorbate plus nanocarrier loading Fe3+ and RSL3 | Ascorbate, iron, RSL3 | Increased specificity to target cancer cells by ascorbate | Iron overload, inhibition of GPX4 and reactive oxygen species overgeneration | 2019 | [111] |